Caribou Biosciences, Inc.

NASDAQ:CRBU

Biotechnology

Healthcare
$0.49 -2.74%

-$0.05 today

Market cap
$52.47M
Beta
2.33
P/E (TTM)
-1.1
EPS (TTM)
-$1.39
52W Low $1.20High $3.54

Volume 1.01M

Average 1.83M

CRBU Other Financing Activities

Financing cash flows not reported separately.

Caribou Biosciences, Inc.NASDAQ: CRBU

Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026

Other financing activities outflow grows to $0

Q1 FY2026 other financing activities was $0, compared with $0 a year earlier. Trailing-twelve-month other financing activities was -$462K.

Context

  • Other financing activities amounted to 0.0% of revenue in FY2025, down 15.3 pp from a year earlier.
  • Other financing activities increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other financing activities holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$115.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMMar 2026
-$462K-222.9% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Financing Activities history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Other Financing Activities vs competitors

How CRBU compares with its peers on the latest reported figures

  • Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -222.9% is the 9th highest of 10, against a peer median of -99.7%.
  • Other financing activities amounts to 4.1% of revenue for CRBU, versus a peer median of 4.3%.
CRBU Competitors
Other Financing Activities for CRBU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HUMAHumacyte, Inc.LTM Mar 2026$91.94M USD-292.0%—4560.7%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$4.34M USD+131.7%-39.1%6.3%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$3.56M USD-43.4%——
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$1.09M USD-26.8%-46.5%3.3%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$462K USD-222.9%—4.1%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$415K USD——184.4%
IVAInventiva S.A.FY2025€236.98K EUR-99.7%—5.3%
PYXSPyxis Oncology, Inc.LTM Mar 2026$104K USD-145.4%—0.8%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$63K USD-146.7%—0.4%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$0 USD+100.0%—0.0%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$0 USD-100.0%——
Peer median (excluding CRBU) —-99.7%-42.8%4.3%

Competitors are the stored peer set for CRBU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(66.92M)(99.42M)(102.07M)(149.11M)(148.13M)
Depreciation & Amortization984K3.64M3.53M3.93M3.65M
Deferred Income Tax0(95K)00(548K)
Stock-Based Compensation3.45M11.72M13.75M16.71M12.68M
Change in Working Capital29.07M(4.11M)(7.32M)(5.11M)(484K)
Accounts Receivables(2.96M)3.46M805K608K272K
Inventory00000
Accounts Payables1.14M(2.72M)1.82M(354K)3.25M
Other Working Capital30.89M(4.85M)(9.94M)(5.37M)(4.01M)
Other Non-Cash Items904K9.02M(1.18M)(4.61M)21.84M
Operating Cash Flow(32.52M)(90.97M)(93.29M)(138.2M)(110.99M)
Capital Expenditures(3.12M)(6.45M)(11.61M)(6.51M)(1.36M)
Acquisitions (Net)00000
Purchases of Investments(173.28M)(339.06M)(394.76M)(304.39M)(150.37M)
Sales of Investments0252.87M338.19M397.49M252.83M
Other Investing Activities(1M)(600K)0(1.61M)1.14M
Investing Cash Flow(176.4M)(93.25M)(68.18M)86.61M102.24M
Debt Repayment1.03M0000
Common Stock Issued321.02M2.13M152.72M15.19M4.82M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.55M01.58M1.53M0
Financing Cash Flow433.43M2.13M154.3M16.72M4.82M
Effect of Forex Changes00000
Net Change in Cash224.51M(182.08M)(7.18M)(34.87M)(3.93M)
Free Cash Flow(35.64M)(97.42M)(104.9M)(144.71M)(112.35M)

Caribou Biosciences, Inc.

NASDAQ:CRBU

Intrinsic Alpha fair value

Locked

Current Price

$0.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.